NCT07230756Not yet recruiting
Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China
A Prospective Cohort Study of Coronary Heart Disease Complicated With Ischemic Mitral Regurgitation in China
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
This project will rely on the established multi-center cooperation platform for total valve disease and based on the Carpentier classification, which is newly proposed and widely recognized by the academic community, and will specifically target the population with coronary heart disease combined with Ischemic Mitral Regurgitation（IMR） to conduct a nationwide, multi-center, single valve disease, prospective cohort. Research. From November 2025 to December 2025, 6,000 patients with coronary heart disease combined with moderate or above IMR were consecutively selected from outpatients or inpatients in 21 regional medical centers across the country, and clinical characteristics, imaging data, and serology were collected. Information, drug/surgical intervention status and clinical outcome indicators were included in the clinical follow-up at baseline, 3 months, 6 months, 12 months and 24 months respectively. The main research objectives are to describe the disease characteristics, treatment status and clinical outcomes of coronary heart disease patients with IMR; to evaluate the current application status of GDMT strategies in IMR diagnosis and treatment practice and its impact on mid- and long-term prognosis. The secondary research objectives are to identify factors affecting prognosis, construct a risk stratification model for mid- and long-term prognosis, and discover new molecular markers. This project will for the first time construct the world's largest clearly defined cohort of coronary heart disease combined with IMR. Its research results can provide high-quality data and decision-making basis for precise diagnosis and treatment of IMR populations. Therefore, this project has important scientific research value and clinical guidance significance.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 6000 (estimated)
- First submitted
- 2 Jan 2025
- Start date
- 10 Nov 2025
- Primary completion date
- 30 Sept 2029
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Coronary artery disease
- NCT number
- NCT07230756
What you commit to
- Study type: Observational
- Planned participants: 6000
- From 10 Nov 2025 to the primary completion date, 30 Sept 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Primary mitral regurgitation (such as mitral valve prolapse, perforation, chordae tendineae rupture, etc.);
- Dilated cardiomyopathy, hypertrophic cardiomyopathy and other diseases;
- Patients who have undergone cardiac valve intervention/surgery.
Other
- Patients within the past year or currently participating in other clinical studies;
- Moderate and above aortic stenosis/regurgitation, mitral stenosis, tricuspid stenosis, etc.;
Who the study is looking for
- Age ≥18 years, secondary mitral regurgitation discovered during outpatient visit or hospitalization;
- Have definite coronary heart disease
- Cardiac ultrasound: consistent with mitral regurgitation caused by myocardial ischemia or myocardial infarction:
- Segmental wall motion abnormality or
- Mitral regurgitation is consistent with Carpentier type IIIb (eccentric regurgitation)
- Cardiac ultrasound prompts: moderate or above ischemic mitral regurgitation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.